Erasmus Hospital

Running trials

• Not yet recruiting

  Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis

  2025-523400-72-00· Phase 2· Vertex Pharmaceuticals Inc.· Source

• Not yet recruiting

  A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis

  2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source

• Not yet recruiting

  A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)

  2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Not yet recruiting

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Recruiting

  A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).

  2026-526139-20-00· Phase 3· Kardigan Inc.· Source

• Recruiting

  ENDO-REAL: Endometriosis and Reproductive Enhancement with Letrozole

  2025-524995-53-00· Phase 4· UZ Brussel· Source

• Recruiting

  ROSY-F: Roll-over Study for Participants Who Have Completed a Previous Clinical Study with Benralizumab (Fasenra) and Benefit from Continued Treatment

  2025-523307-29-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

  NCT07771465· Phase 3· Kardigan, Inc.· Source

• Recruiting

  A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

  NCT07673887· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

  NCT07725939· Phase 2· UCB Biopharma SRL· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07481981· Phase 3· Insmed Incorporated· Source

• Recruiting

  A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)

  NCT07656415· Phase 3· Agios Pharmaceuticals, Inc.· Source

• Recruiting

  An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

  NCT07665437· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Pridopidine Phase 3 Study in Huntington's Disease

  NCT07609108· Phase 3· Prilenia· Source

• Recruiting

  A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease

  2025-524001-33-00· Phase 2· Immunovant Sciences GmbH· Source

• Recruiting

  An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis

  NCT07620392· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year

  2025-521590-13-00· Phase 3· Janssen Cilag International· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07318597· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

  NCT07285655· Phase 3· Liquidia Technologies, Inc.· Source

• Recruiting

  An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

  NCT07365332· Phase 3· Inhibikase Therapeutics· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  NCT07351045· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

  NCT07456033· Phase 3· GlaxoSmithKline· Source

• Recruiting

  Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

  NCT07286058· Phase 3· Takeda· Source

• Recruiting

  Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

  NCT07404865· Phase 3· Vor Biopharma· Source

• Recruiting

  A Study of the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy.

  2025-522553-19-00· Phase 2/3· Kardigan Inc.· Source

• Recruiting

  AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

  NCT07339423· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

  NCT07298044· Phase 4· Bayer· Source

• Recruiting

  A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

  NCT07210723· Phase 2/3· Kardigan, Inc.· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  NCT07392190· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

  NCT07222332· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)

  NCT07234838· Jonathan Krygier· Source

• Recruiting

  The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension

  NCT07359599· Phase 4· Ziekenhuis Oost-Limburg· Source

• Recruiting

  A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT07225569· Phase 2· Sanofi· Source

• Recruiting

  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  NCT07221188· Phase 3· GlaxoSmithKline· Source

• Enrolling by invitation

  Characterisation of a Population of Adults Suffering From Cystic Fibrosis in a Belgian Reference Center

  NCT07442682· Erasme University Hospital· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have not Responded to or who Cannot Tolerate TNF and/or JAK Inhibitors

  2025-521034-28-00· Phase 2· F. Hoffmann-La Roche AG· Source

• Recruiting

  A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  NCT07221253· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

  NCT06804811· Phase 3· Incyte Corporation· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

  2024-516652-18-00· Phase 3· Amgen Inc.· Source

• Enrolling by invitation

  Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease

  NCT07548801· Université Libre de Bruxelles· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

  NCT06919965· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

  2024-517529-26-00· Phase 3· Dianthus Therapeutics Inc.· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Eli Lilly and Company· Source

Showing 50 of 150.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease10 recruiting
• Fatty liver disease (MASLD/MASH)9 recruiting
• High blood pressure6 recruiting
• Liver and biliary tract cancer5 recruiting
• Pulmonary arterial hypertension5 recruiting
• Dilated cardiomyopathy4 recruiting
• Hidradenitis suppurativa3 recruiting
• Obesity3 recruiting
• Psoriasis3 recruiting
• Sickle cell disease3 recruiting
• Ulcerative colitis3 recruiting
• Amyloidosis2 recruiting
• Asthma2 recruiting
• Cystic fibrosis2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Graves' disease and hyperthyroidism2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Liver cirrhosis2 recruiting
• Multiple sclerosis2 recruiting
• Pancreatic cancer2 recruiting
• Rheumatoid arthritis2 recruiting
• Type 2 diabetes2 recruiting
• ANCA-associated vasculitis1 recruiting
• Aortic aneurysm1 recruiting
• Aortic stenosis1 recruiting
• Bladder cancer1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Colorectal cancer1 recruiting
• COPD1 recruiting
• Endometriosis1 recruiting
• Epilepsy1 recruiting
• Friedreich ataxia1 recruiting
• Huntington's disease1 recruiting
• IgA nephropathy1 recruiting
• Lupus (SLE)1 recruiting
• Myasthenia gravis1 recruiting
• Parkinson disease1 recruiting
• Psoriatic arthritis1 recruiting
• Sjögren's disease1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Thalassaemia1 recruiting
• Type 1 diabetes1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  An Open-Label Extension Study for Participants with PAH Who Have Previously Participated in a Clinical Trial with PF-07868489

  2025-521155-23-00· Phase 2· Pfizer Inc.· Source

• Terminated

  A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

  NCT06987968· Phase 2· Genfit· Source

• Completed

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

  NCT06926660· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

  NCT06699849· Phase 2· CSL Behring· Source

• Completed

  A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY)

  NCT06684847· Phase 3· Argenx· Source

• Completed

  A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium

  NCT06677892· Takeda· Source

• Active, not recruiting

  A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

  NCT06422884· Phase 2· Endeavor Biomedicines, Inc.· Source

• Completed

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open- labeled Long-term Extension Treatment with Aticaprant

  2024-511557-21-00· Phase 3· Janssen Cilag International· Source

• Completed

  A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction

  2023-508736-62-00· Phase 2· Cardurion Pharmaceuticals Inc.· Source

• Completed

  A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

  NCT06238817· Phase 3· Incyte Corporation· Source

• Completed

  A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis

  2023-504564-42-00· Phase 2· Anaptysbio Inc.· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

  NCT06257875· Phase 2· AbbVie· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06212999· Phase 3· Incyte Corporation· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· GB002, Inc.· Source

• Completed

  Probiotics to Actively Counter Ventilator Associated Pneumonia (PROACT)

  NCT06092554· University of Bari· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

  NCT06066515· Phase 3· Boehringer Ingelheim· Source

• Completed

  Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy

  2022-502316-36-00· Phase 4· Myokardia Inc.· Source

• Completed

  A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

  NCT06137742· Phase 1/2· Pfizer· Source

• Terminated

  A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

  NCT06032546· Phase 2· AbbVie· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT06040086· Phase 3· AstraZeneca· Source

• Completed

  Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL)

  NCT05557942· Phase 3· Aerovate Therapeutics Inc.· Source

• Active, not recruiting

  An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma

  2022-501463-40-01· Phase 3· Servier Affaires Medicales· Source

• Completed

  A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon)

  2022-501538-44-00· Phase 3· Amgen Inc.· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Amgen· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy

  NCT05582395· Phase 3· Myokardia Inc.· Source

• Active, not recruiting

  A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

  NCT05785611· Phase 3· Alfasigma S.p.A.· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA

  NCT05992142· Phase 4· Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW· Source

• Completed

  Phase 2b Study of GSK4532990 in Adults With NASH

  NCT05583344· Phase 2· GlaxoSmithKline· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT05620823· Phase 3· Incyte Corporation· Source

• Completed

  A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  NCT05651711· Phase 3· Amgen· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

  NCT05347095· Phase 3· Janssen-Cilag Ltd.· Source

• Completed

  A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

  NCT05147805· Phase 2· Insmed Incorporated· Source

• Active, not recruiting

  Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

  NCT05263934· Phase 3· GlaxoSmithKline· Source

• Completed

  Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and Confirmatory Study of AV-101 in Patients with PAH

  NCT05036135· Phase 2/3· Aerovate Therapeutics Inc.· Source

• Completed

  A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension (PAH) Patients.

  NCT04811092· Phase 3· Acceleron Pharma Inc.· Source

• Completed

  Chemical and Mechanical Angioplasty for Vasospasm (SAVEBRAIN)

  NCT05268445· Erasme University Hospital· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source

• Completed

  A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

  NCT04945460· Phase 2· Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA· Source

• Completed

  A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

  NCT04896008· Phase 3· Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA· Source

• Completed

  An open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma

  2024-514905-79-00· Phase 1/2· Alligator Bioscience AB· Source

• Completed

  A Long-term Follow-up Study of Sotatercept for PAH Treatment

  NCT04796337· Phase 3· Acceleron Pharma Inc.· Source

• Completed

  A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

  NCT04732221· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Completed

  Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.

  NCT04464564· Phase 3· Otsuka Pharmaceutical Development & Commercialization Inc.· Source

• Completed

  A Study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated with Atezolizumab and Bevacizumab

  2023-503229-21-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Completed

  Verapamil SR in Adults With Type 1 Diabetes

  NCT04545151· Phase 2· Medical University of Graz· Source

• Completed

  Validation of Kinocardiography, a New Technology Measuring Cardiac Mechanical Activity Via Accelerometers and Gyroscopes

  NCT04772807· Erasme University Hospital· Source

• Completed

  A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

  NCT04704154· Phase 2· Bayer· Source

Showing 50 of 77.

Conditions

Diseases this institution publishes on or runs trials for.

• Pulmonary arterial hypertension12 works · 23 trials
• Hidradenitis suppurativa12 works · 11 trials
• Friedreich ataxia3 works · 2 trials